Corrigendum to ‘Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials’: [ESMO Open Volume 7, Issue 2, (2022), 100455](S2059702922000710)(10.1016/j.esmoop.2022.100455)

D. König*, S. Schär, D. Vuong, M. Guckenberger, K. Furrer, I. Opitz, W. Weder, S. I. Rothschild, A. Ochsenbein, A. Zippelius, A. Addeo, M. Mark, E. I. Eboulet, S. Hayoz, S. Thierstein, D. C. Betticher, H. B. Ris, R. Stupp, A. Curioni-Fontecedro, S. PetersM. Pless, M. Früh

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret that an affiliation for M. Früh was missing. This should be as follows: M. Früh6,15 6Department of Medical Oncology, University Hospital of Bern (Inselspital), Bern, Switzerland 15Department of Medical Oncology/Hematology, Cantonal Hospital of St. Gallen, St. Gallen, SwitzerlandAll other affiliations are correct. The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Article number100494
JournalESMO Open
Volume7
Issue number3
DOIs
StatePublished - Jun 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials’: [ESMO Open Volume 7, Issue 2, (2022), 100455](S2059702922000710)(10.1016/j.esmoop.2022.100455)'. Together they form a unique fingerprint.

Cite this